Please select the option that best describes you:
Are there any data to guide choice of immunotherapy agent in first line treatment for extensive stage small cell lung cancer?
E.g. chemo/durvalumab vs chemo/atezolizumab?
Answer from: Medical Oncologist at Academic Institution
Both the addition of durvalumab and atezolizumab to platinum etoposide resulted in a modest improvement in median progression free, overall survival and saw twelve-month overall survival rates just above 50%. The ECOG-ACRIN phase II trial of nivolumab added to platinum etoposide also improved PFS an...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The short answer is no, there is no comparative data that would allow us to distinguish any clinical difference between the two FDA-approved, first-line immune checkpoint inhibitors, atezolizumab or durvalumab, when used in combination with platinum plus etoposide for ES-SCLC. While cross-trial comp...
Answer from: Medical Oncologist at Academic Institution
There are two checkpoint inhibitors, both targeting PD-L1, approved for use in the first-line setting for ES-SCLC and either would be appropriate in eligible patients. Atezolizumab was approved in March 2019 based on the IMpower 133 trial that demonstrated a significant improvement in survival when ...